Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
Bing Bai, Alexandr Belovodskiy, Mostofa Abu Hena, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2905-2925
Closed Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 142
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 98
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Daniel W. Kneller, Hui Li, G.N. Phillips, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Kai S. Yang, Sunshine Z. Leeuwon, Shiqing Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8686-8698
Open Access | Times Cited: 92
Peptidomimetics: An Overview of Recent Medicinal Chemistry Efforts toward the Discovery of Novel Small Molecule Inhibitors
Giovanna Li Petri, Simona Di Martino, Maria De Rosa
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7438-7475
Closed Access | Times Cited: 66
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 46
SARS-CoV-2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals
Sizhu Amelia Chen, Elena Arutyunova, Jimmy Lu, et al.
ACS Central Science (2023) Vol. 9, Iss. 4, pp. 696-708
Open Access | Times Cited: 43
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo Augusto Massarico Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 41
Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
Elisa Costanzi, Maria Kuzikov, Francesca Esposito, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11779-11779
Open Access | Times Cited: 71
Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors
Julia Stille, Jevgenijs Tjutrins, Guanyu Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114046-114046
Open Access | Times Cited: 60
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
Thanigaimalai Pillaiyar, Philipp Flury, Nadine Krüger, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 9376-9395
Closed Access | Times Cited: 55
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 44
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 26
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Structural biology of SARS-CoV-2 Mpro and drug discovery
Yinkai Duan, Haofeng Wang, Zhenghong Yuan, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102667-102667
Closed Access | Times Cited: 22
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 22
Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
A. Ravi Kumar, Haifa El Kilani, Alina Metzen, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1722-1730
Open Access | Times Cited: 49
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 41
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Tika R. Malla, Lennart Brewitz, Dorian-Gabriel Muntean, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7682-7696
Open Access | Times Cited: 31
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
Yuya Hirose, Naoya Shindo, Makiko Mori, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 13852-13865
Closed Access | Times Cited: 31
Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition
Jimmy Lu, Sizhu Amelia Chen, Muhammad Bashir Khan, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 30
Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease
Chamandi S. Dampalla, Athri D. Rathnayake, Anushka C. Galasiti Kankanamalage, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7818-7832
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top